Axel Le Cesne, Institut Gustave Roussy, Villejuif, France
Javier Martín-Broto, Department of Medical Oncology, University Hospital Virgen del Rocio and Institute of Biomedicine of Sevilla (IBIS) (HUVR, CSIC, University of Sevilla), Seville, Spain
Peter Reichardt, Helios Klinikum Berlin-Buch, Department of Oncology and Palliative Care, Sarcoma Center Berlin-Brandenburg and Directorate of the Cancer Center Berlin-Buch, Berlin, Germany
Piero Picci, I.S.G. Italian Sarcoma Group, Bologna, Italy
Jean-Yves Blay, Centre Léon Bérard, Lyon, France


Introduction: The aim of this analysis is to understand the treatment of advanced Soft Tissue Sarcomas (aSTS) in the real-life setting, with a special focus on the use of trabectedin (Yondelis®) according to treatment line and histological subtype. Materials and Methods: The data source for this study was the Oncology AdvantageTM (OA), which is a trademark of IQVIA Information S.A. We utilized anonymized patient-level data on aSTS from OA of cancer-treating physicians in France, Germany, Spain, and Italy from January 2015 to December 2018. Results: A total of 5,298 patients with aSTS were enrolled, 36% of patients were diagnosed with leiomyosarcoma, and 21% with liposarcoma. The vast majority of patients with all studied histologies received anthracyclinebased regimen as 1st line treatment, while trabectedin was the most common 2nd line therapy (around 30% of patients) and pazopanib was the regimen most frequently used in the 3rd line setting. Among the 2,257 patients who were treated with trabectedin at any line, almost 70% received this agent right after a doxorubicin-based therapy, with a median of 6.9 cycles of trabectedin in 2nd line per patient in the studied period. Conclusions: The studied database illustrates how the management of aSTS at daily clinical practice is well aligned with recommendations of International and National Guidelines: anthracycline-based therapy is the most common regimen in the 1st line setting while trabectedin is the agent most frequently used as 2nd line therapy.



Keywords: Soft Tissue Sarcoma. Trabectedin. L-sarcoma. Leiomyosarcoma. Liposarcoma.